前列腺良性增生及其癌组织微小RNA-19b-1-5p表达
EXPRESSION OF MIR-19B-1-5P IN TISSUES OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER
黄振 1穆克飞 1杜建伟 1刘勇1
作者信息
- 1. 青岛大学附属医院泌尿外科,山东青岛266003
- 折叠
摘要
目的 了解良性前列腺增生组织和前列腺癌组织中微小RNA(miR)-19b-1-5p的表达,分析其与临床病理特征的关系.方法 应用实时荧光定量聚合酶链反应方法,检测68例良性前列腺增生组织和77例前列腺癌组织中miR-19b-1-5p的表达,分析miR-19b-1-5p的相对表达量与前列腺癌临床病理特征之间的关系.结果 miR-19b-1-5p在良性前列腺增生组织中高表达,而在前列腺癌组织内低表达,两组比较差异有显著性(t=24.87,P＜0.05);miR-19b-1-5p的相对表达量与前列腺癌Gleason评分、临床分期有关(t=13.08、7.55,P＜0.05).结论 miR-19b-1-5p可能作为一种潜在的肿瘤标志物用于前列腺癌的早期诊断及预后评估.
Abstract
Objective To investigate the expression of microRNA (miRNA,miR)-19b-1-5p in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and analyze its association with clinicopathology.Methods The expression levels of 68 BPH tissues and 77 PCa tissues were detected using real-time quantitative polymerase chain reaction (Real-time PCR) and its correlation with Gleason Grading and clinical characters were analyzed.Results Employing real time fluorescent quantitative polymerase chain reaction technique,the expression of miR 19b-1-5p in 68 cases of BPH tissue and 77 cases of prostate cancer tissue was detected,and the association of relative expression of miR-19b 1-5p with Gleason Grade and clinical features of the cancer was analyzed (t=13.08,7.55;P＜0.05).Conclusion miR 19b-1-5p may be used as a potential biomarker in early diagnosis of pros tate cancer and its prognosis evaluation.
关键词
前列腺肿瘤/前列腺增生/微小RNA-19b-1-5p/病理学,临床Key words
prostatic neoplasms/benign prostatic hyperplasia/miRNA-19b-1-5p/pathology, clinical引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据